您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > HNHA
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
HNHA
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
HNHA图片
CAS NO:926908-04-5
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍
HNHA 是一种有效的组蛋白去乙酰化酶 (HDAC) 抑制剂。 HNHA 通过 p21 诱导将细胞周期阻滞在 G1/S 期。 HNHA 抑制肿瘤生长和肿瘤新血管形成。 HNHA 可能是一种有效的抗乳腺癌药物。
Cas No.926908-04-5
别名N-羟基-7-(2-萘硫基)-庚酰胺,Histone Deacetylase Inhibitor VI
化学名N-hydroxy-7-(2-naphthalenylthio)-heptanamide
Canonical SMILESc1ccc2c(c1)cc(cc2)SCCCCCCC(NO)=O
分子式C17H21NO2S
分子量303.4
溶解度≤20mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 100 nM

HNHA is an HDAC inhibitor.

Histone acetylation is regulated by two covalent modifying enzymes, acetylases and deacetylases, and plays a key role in gene expression of eukaryotes. It has been revealed that histone deacetylase (HDAC), which is overexpressed in several tumor cells. plays a critical role in carcinogenesis. Moreover, plenty of studies have showed that the expression of tumor suppressors including p53, p21, and gelsolin, are repressed, whereas, tumor activators including hypoxia-induced factor-1 and vascular endothelial growth factor, are up-regulated in HDAC-overexpressed cells.

In vitro: Previous study found that HNHA was able to inhibit in-vitro HDAC enzyme activity as well as proliferation of human fibrosarcoma cells (HT1080). In addition, treatment of cells with HNHA could elicite histone hyperacetylation resulting in an up-regulation of cell cycle arrest, p21 transcription, and an inhibition of HT1080 cell invasion [1].

In vivo: The effects of HNHA on human cancer cells bearing xenograph mice was examined. Results showed that as expected, HNHA could dramatically reduce tumor volume as to (vehicle) control. In addition, HNHA had a stronger potency than that of SAHA, which implied that the pharmacological potency of HNHA was better than SAHA in vivo [1].

Clinical trial: So far, no clinical study has been conducted.

Reference:
1.  Kim, D.H.,Lee, J.,Kim, K.N., et al. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor. Biochemical and Biophysical Research Communications 356, 233-238 (2007).